title: [Combination of Jianpi Liqi Yiliu Formula with Cytokine-induced Killer Cell Treatment for Advanced Hepatocellular Carcinoma].
abstract: OBJECTIVE
  To evaluate the clinical efficacy of Jianpi Liqi Yiliu Formula (JLYF) combined with cytokine-induced killer (CIK) cells for treating patients with advanced hepatocellular carcinoma (HCC).
  
  
  METHODS
  Between January 2011 and January 2014, 60 advanced HCC patients were enrolled in this study, who were assigned to the treatment group and the control group according to their willingness for taking JLYF, 30 cases in each group. All patients received CIK cell treatment: 1 x 10⁹-3 x 10⁹ each time, by intravenous dripping from the 1st day to the 3rd day, once per day. Besides, patients in the treatment group took JLYF decoction, while those in the control group took Chinese medical decoction by syndrome typing. All patients received treatment of at least two cycles. The time to progression (TTP) , overall survival (OS), disease control rate (DCR), performance status scale (PS), Child-Pugh scale, and adverse reactions were observed, and subgroup analyzed.
  
  
  RESULTS
  To May 31, 2014, all patients reached the clinical endpoint. TTP was 3.5 months (95% Cl: 3.30-4.10) in the treatment group, better than that (2.5 months, 95% CI: 2.32-2.68) of the control group (P < 0.05). DCR was 36.7% in the treatment group and 30.0% in the control group (P > 0.05). OS was 5.2 months (95% CI: 4.53-5.87) in the treatment group and 4.6 months (95% CI: 4.06-5.14) in the control group (P > 0.05). The PS scale was 1.60 ± 0.10 after treatment, lower than that (1.80 ± 0.09) before treatment in the treatment group (P < 0.05). When the PS scale was 0-2 or Child-Pugh scale was class A, TTP was longer in the treatment group than in the control group (P < 0.05). No adverse reaction occurred in the two groups during the treatment course.
  
  
  CONCLUSIONS
  The combination of JLYF with ClK cell treatment could prolong advanced HCC patients' TTP, improve PS scale, as compared with syndrome typed Chinese medical decoction treatment group. Besides, when the PS scale was 0-2 or Child-Pugh scale was class A, it was a better treatment program for advanced HCC patients.
authors.forename: Shun-qin
authors.initials: SQ
authors.lastname: Long
authors.forename: Xiao-xuan
authors.initials: XX
authors.lastname: Zhang
authors.forename: Xiao-bing
authors.initials: XB
authors.lastname: Yang
authors.forename: Yu-shu
authors.initials: YS
authors.lastname: Zhou
authors.forename: Wen-feng
authors.initials: WF
authors.lastname: He
authors.forename: Gui-ya
authors.initials: GY
authors.lastname: Liao
authors.forename: Yu-shu
authors.initials: YS
authors.lastname: Ouyang
authors.forename: Qiu-ping
authors.initials: QP
authors.lastname: Li
authors.forename: Jin-peng
authors.initials: JP
authors.lastname: Huang
authors.forename: Hong
authors.initials: H
authors.lastname: Deng
authors.forename: Zong-qi
authors.initials: ZQ
authors.lastname: Pan
authors.forename: Shu-jing
authors.initials: SJ
authors.lastname: Xiao
authors.forename: Jiao-zhi
authors.initials: JZ
authors.lastname: Cai
authors.forename: Wan-yin
authors.initials: WY
authors.lastname: Wu
mesh_terms: D006528:Carcinoma, Hepatocellular / Q000628:therapy*; D064987:Cell- and Tissue-Based Therapy; D055612:Cytokine-Induced Killer Cells / Q000166:cytology*; D018450:Disease Progression; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use*; D006801:Humans; D008113:Liver Neoplasms / Q000628:therapy*
chemical_list: D004365:Drugs, Chinese Herbal